Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14839MR)

This product GTTS-WQ14839MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14839MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ840MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ10602MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ324MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ2516MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ3882MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ1170MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ10465MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2541546
GTTS-WQ14439MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW